Business Wire

Autel launches new MaxiCharger DC Compact worldwide

17.1.2023 14:57:00 EET | Business Wire | Press release

Share

Autel is today announcing the launch of an innovative electric vehicle DC charger, the MaxiCharger DC Compact, providing up to 40kW of DC power for the U.S. version and 47kW of power for the European version. The MaxiCharger DC Compact comes with two charging cables, allowing two vehicles to charge simultaneously with dynamic power distribution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005624/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The MaxiCharger DC Compact comes with options like a credit card reader and a pedestal. (Photo: Business Wire)

The MaxiCharger DC Compact is sleek and compact with a 21.5-inch LCD touchscreen for user-friendly interaction and advertising capability. It can be hung on a wall, placed on a pedestal, or set on wheels for ultimate portability. The MaxiCharger DC Compact is perfect for businesses wanting to provide their customers with a quick top-up charge option without breaking the bank on a DC Fast charger. It is also an excellent option for commercial fleets that need a slower DC charge for their fleet vehicles to charge overnight.

“This is an exciting launch for Autel as we establish ourselves as the worldwide leader in electric vehicle charging,” said Kelvin Cao, Vice President of Global Marketing at Autel. “The MaxiCharger DC Compact is small in size but a powerful addition to our growing portfolio of EV chargers, and a great fit for businesses needing an affordable, yet fast EV charger.”

Elevated Efficiency with Dual Ports

The MaxiCharger DC Compact is designed to increase charging efficiency, providing up to 47kW of power with dual-ports. It can charge 2 vehicles simultaneously, sharing power dynamically between the two vehicles. A 30 minute charge equates to about 130 km of range, saving on charging time.

Smart Advertising and Communication Platform

Powered by the smart operating system, Android 10, with a user-friendly 21.5-inch LCD touchscreen and enhanced advertising placement capability, the MaxiCharger DC Compact communicates with, engages and attracts customers, generating new revenue streams.

Compatibility

The MaxiCharger DC Compact is OCPP1.6 capable. It is compatible with CCS1, CCS2 and CHAdeMO charging cables, depending on operator and regional needs. With the Autel Charge app, RFID cards, and credit card capability, the MaxiCharger DC Compact offers convenient ways for end users to pay for and begin their charging sessions. It offers 4G, Wi-Fi, and ethernet connectivity options and supports regular over-the-air software updates with an internet connection.

Cloud Platform

The MaxiCharger DC Compact is powered on the backend using Autel’s smart charge cloud platform. The cloud platform helps charge point operators view, monitor, and analyze charger data in real-time. Operators can also view revenue and user data, and set advertisements all from the cloud platform. Autel’s cloud management platform allows all operators to efficiently and conveniently manage their chargers in one easy-to-use interface.

Become a Dealer

If you are interested in becoming a dealer for the MaxiCharger DC Compact and for all of the MaxiCharger series of EV chargers, head over to the Autel website and fill out our dealer form. If you are interested in purchasing a MaxiCharger DC Compact, contact your local Autel sales representative or contact us below.

About Autel

Autel designs, engineers, and manufactures some of the most advanced products for residential and commercial users, offering hardware, software, apps, and cloud-based solutions to cover almost every use case and application.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael Madden
marketing@autel.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye